MIDATECH PHARMA
Technologies | GNP Technology

Midatech glycan-coated GNP

Midacore® GNP Technology

Midatech’s primary platform technology is based on carbohydrate-coated gold nanoparticle (GNP) drug conjugates.

Midatech’s core technology platform is based on a patented form of ultra-small gold nanoparticles (GNPs), which have the ability to improve key properties of new and existing drugs bound to their surface. The biodistribution of GNPs is strongly influenced by their size and surface characteristics.  Surface-bound carbohydrates and other ligands, including peptides, are attached to enhance uptake of the GNP into individual cell types, primarily through cell-surface receptor interactions.

Midatech is applying Midacore® to the discovery and development of novel treatments for orphan cancers, especially those affecting the brain and liver.   General or specific targeting agents have been shown to enhance both delivery of peptides to antigen-presenting cells (immunotherapy approaches) and delivery of a therapeutic payload into the tumour cell itself (chemotherapy approaches).  More effective targeting of drugs spares healthy cells and reduces the side-effect profile associated with conventional chemotherapy. GNP technology is the latest generation of nanomedicine, with demonstrated safety in the clinic to date.

The key advantages the Midacore® platform technology are:

GNPs comprise of a core of gold metal atoms to which an organic layer of carbohydrates or glycans (e.g. glucose, galactose or lactose) are attached via gold-sulphur bonds. The carbohydrate layer stabilises the metallic core (passivation) and makes the particle both water-soluble and biocompatible.

Linkers for therapeutic agents (e.g. small molecules and chemotherapeutics) and peptides (e.g. insulin) are attached to the gold core during the self-formation process. This process involves intricate yet uncomplicated synthesis that produces multi-functional particles that can deliver multiple drug molecules to the targeted site.

Intracellular release of payloads is via glutathione (GSH)-mediated displacement from the GNP surface. GSH is the most abundant thiol species in the cytoplasm and the main reducing agent in biochemical processes, providing a potential in situ releasing source in living cells. The intracellular GSH concentration (1-10 mM) is substantially higher than extracellular levels (2uM in plasma). In cancer, the differential in GSH concentrations is even more marked between tumour cells and normal cells, thus providing a useful mechanism for selective intracellular release.

The GNP platform has potential uses in Oncology, Immunology/ Auto-immunology, Vaccines and Neurology. 

In addition to our internal research activities Midatech Pharma participates in European collaborative research programmes, currently the H2020 projects NANOFACTURING and IMMUNOSHAPE.  Midatech also partners with other companies seeking enhanced delivery of their drug products in development.

Technologies
GNP Technology

Midacore® GNP Technology

Midatech’s primary platform technology is based on carbohydrate-coated gold nanoparticle (GNP) drug conjugates.

Midatech’s core technology platform is based on a patented form of ultra-small gold nanoparticles (GNPs), which have the ability to improve key properties of new and existing drugs bound to their surface. The biodistribution of GNPs is strongly influenced by their size and surface characteristics.  Surface-bound carbohydrates and other ligands, including peptides, are attached to enhance uptake of the GNP into individual cell types, primarily through cell-surface receptor interactions.

Midatech is applying Midacore® to the discovery and development of novel treatments for orphan cancers, especially those affecting the brain and liver.   General or specific targeting agents have been shown to enhance both delivery of peptides to antigen-presenting cells (immunotherapy approaches) and delivery of a therapeutic payload into the tumour cell itself (chemotherapy approaches).  More effective targeting of drugs spares healthy cells and reduces the side-effect profile associated with conventional chemotherapy. GNP technology is the latest generation of nanomedicine, with demonstrated safety in the clinic to date.

The key advantages the Midacore® platform technology are:

GNPs comprise of a core of gold metal atoms to which an organic layer of carbohydrates or glycans (e.g. glucose, galactose or lactose) are attached via gold-sulphur bonds. The carbohydrate layer stabilises the metallic core (passivation) and makes the particle both water-soluble and biocompatible.

Linkers for therapeutic agents (e.g. small molecules and chemotherapeutics) and peptides (e.g. insulin) are attached to the gold core during the self-formation process. This process involves intricate yet uncomplicated synthesis that produces multi-functional particles that can deliver multiple drug molecules to the targeted site.

Intracellular release of payloads is via glutathione (GSH)-mediated displacement from the GNP surface. GSH is the most abundant thiol species in the cytoplasm and the main reducing agent in biochemical processes, providing a potential in situ releasing source in living cells. The intracellular GSH concentration (1-10 mM) is substantially higher than extracellular levels (2uM in plasma). In cancer, the differential in GSH concentrations is even more marked between tumour cells and normal cells, thus providing a useful mechanism for selective intracellular release.

The GNP platform has potential uses in Oncology, Immunology/ Auto-immunology, Vaccines and Neurology. 

In addition to our internal research activities Midatech Pharma participates in European collaborative research programmes, currently the H2020 projects NANOFACTURING and IMMUNOSHAPE.  Midatech also partners with other companies seeking enhanced delivery of their drug products in development.

© Copyright 2018 Midatech Pharma PLC